EdgarLookup

Organogenesis Holdings Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Organogenesis Holdings Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $150.86M Nov 6, 2025
Q2 2025 Jun 30, 2025 $101.01M Aug 7, 2025
Q1 2025 Mar 31, 2025 $86.69M May 8, 2025
Q3 2025 Sep 30, 2024 $115.18M Nov 6, 2025
Q2 2025 Jun 30, 2024 $130.23M Aug 7, 2025
Q1 2025 Mar 31, 2024 $109.98M May 8, 2025
Q3 2024 Sep 30, 2023 $108.53M Nov 12, 2024
Q2 2024 Jun 30, 2023 $117.32M Aug 8, 2024
Q1 2024 Mar 31, 2023 $107.64M May 9, 2024
Q3 2023 Sep 30, 2022 $116.86M Nov 9, 2023
Q2 2023 Jun 30, 2022 $121.40M Aug 9, 2023
Q2 2022 Mar 31, 2022 $97.12M Aug 9, 2022
Q3 2022 Mar 31, 2022 $97.12M Nov 9, 2022
Q1 2023 Mar 31, 2022 $97.12M May 10, 2023
Q3 2022 Dec 31, 2021 $467.36M Nov 9, 2022
Q2 2022 Dec 31, 2021 $467.36M Aug 9, 2022
Q3 2022 Sep 30, 2021 $113.75M Nov 9, 2022
Q2 2022 Jun 30, 2021 $123.20M Aug 9, 2022
Q1 2022 Mar 31, 2021 $102.55M May 10, 2022
Q3 2021 Sep 30, 2020 $100.80M Nov 9, 2021

Revenue (Net Sales) — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2018 Sep 30, 2018 $0 Nov 9, 2018
Q2 2018 Jun 30, 2018 $0 Aug 7, 2018
Q1 2018 Mar 31, 2018 $0 May 10, 2018
Q3 2017 Sep 30, 2017 $0 Nov 14, 2017
Q2 2017 Jun 30, 2017 $0 Aug 11, 2017
Q1 2017 Mar 31, 2017 $0 May 12, 2017
Q3 2016 Sep 30, 2016 $0 Nov 18, 2016

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $21.57M Nov 6, 2025
Q2 2025 Jun 30, 2025 ($9.39M) Aug 7, 2025
Q1 2025 Mar 31, 2025 ($18.84M) May 8, 2025
Q3 2025 Sep 30, 2024 $12.33M Nov 6, 2025
Q2 2025 Jun 30, 2024 ($17.04M) Aug 7, 2025
Q1 2025 Mar 31, 2024 ($2.10M) May 8, 2025
Q3 2024 Sep 30, 2023 $3.17M Nov 12, 2024
Q2 2024 Jun 30, 2023 $5.32M Aug 8, 2024
Q1 2024 Mar 31, 2023 ($2.97M) May 9, 2024
Q3 2023 Sep 30, 2022 $215.0K Nov 9, 2023
Q2 2023 Jun 30, 2022 $8.74M Aug 9, 2023
Q3 2022 Mar 31, 2022 ($913.0K) Nov 9, 2022
Q2 2022 Mar 31, 2022 ($913.0K) Aug 9, 2022
Q1 2023 Mar 31, 2022 ($913.0K) May 10, 2023
Q3 2022 Dec 31, 2021 $94.20M Nov 9, 2022
Q2 2022 Dec 31, 2021 $94.20M Aug 9, 2022
Q3 2022 Sep 30, 2021 $12.58M Nov 9, 2022
Q2 2022 Jun 30, 2021 $20.69M Aug 9, 2022
Q1 2022 Mar 31, 2021 $9.94M May 10, 2022
Q3 2021 Sep 30, 2020 $20.76M Nov 9, 2021

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $20.73M Nov 6, 2025
Q2 2025 Jun 30, 2025 ($12.58M) Aug 7, 2025
Q1 2025 Mar 31, 2025 ($26.75M) May 8, 2025
Q3 2025 Sep 30, 2024 $6.24M Nov 6, 2025
Q2 2025 Jun 30, 2024 ($13.89M) Aug 7, 2025
Q1 2025 Mar 31, 2024 ($3.85M) May 8, 2025
Q3 2024 Sep 30, 2023 $8.05M Nov 12, 2024
Q2 2024 Jun 30, 2023 $9.75M Aug 8, 2024
Q1 2024 Mar 31, 2023 ($4.00M) May 9, 2024
Q3 2023 Sep 30, 2022 $1.78M Nov 9, 2023
Q2 2023 Jun 30, 2022 $11.94M Aug 9, 2023
Q1 2023 Mar 31, 2022 ($128.0K) May 10, 2023
Q2 2022 Mar 31, 2022 ($128.0K) Aug 9, 2022
Q3 2022 Mar 31, 2022 ($128.0K) Nov 9, 2022
Q3 2022 Dec 31, 2021 $72.22M Nov 9, 2022
Q2 2022 Dec 31, 2021 $72.22M Aug 9, 2022
Q3 2022 Sep 30, 2021 $16.26M Nov 9, 2022
Q2 2022 Jun 30, 2021 $23.59M Aug 9, 2022
Q1 2022 Mar 31, 2021 $12.62M May 10, 2022
Q3 2021 Sep 30, 2020 $22.80M Nov 9, 2021